Navigation Links
New Study Reveals Protein Produced by Spleen Reduces Risk of Deadly Lung Infection
Date:1/23/2010

In a lead study published in the American Journal of Respiratory Critical Care Medicine, Ping Wang, MD Wang and his colleagues used an experimental medicine called MFG-E8 on the heels of ischemia and found that it significantly lowered the risk for ischemia reperfusion injury, a condition caused when blood flow to the organ is interrupted (during surgery, injury or disease) and then re-established.

Manhasset, NY (Vocus) January 22, 2010 -- One to five percent of people who undergo surgery for gastrointesintal problems experience a potentially life-threatening condition: a temporary loss of oxygen that can set in motion a rogue inflammatory response that can lead to organ failure.

Ping Wang, MD, a scientist at The Feinstein Institute for Medical Research in Manhasset, NY, is testing the benefits of an experimental medicine that can clear away dying cells and reduce the risk for ischemia reperfusion injury. In a lead study published in the American Journal of Respiratory Critical Care Medicine, Dr. Wang and his colleagues used an experimental medicine called MFG-E8 on the heels of ischemia and found that it significantly lowered the risk for ischemia reperfusion injury, a condition caused when blood flow to the organ is interrupted (during surgery, injury or disease) and then re-established. Normally, when tissue suffers from a temporary loss of oxygen, the body makes an unusual response when the oxygen starts to flow again. It sets off an inflammatory response. These inflammatory cells actually target tissue and can trigger multiple organ failure. The lung is most susceptible to this type of injury, which is why in humans it can be deadly.

MFG-8 blocked the acute lung injury in an animal model of ischemic reperfusion. Fifty percent of the animals exposed to MFG-8 survived, according to Dr. Wang. MFG-8 is a protein normally produced by the spleen to enhance clearance of dying cells. The Feinstein scientists made a recombinant human protein. The idea to use the protein emerged after their studies showed that MFG-8 levels drop markedly on the heels of ischemia reperfusion. Spleen cells just can't produce enough of the substance to clean up the dead or dying cells. If the cells are not removed -- and this cellular garbage continues to accumulate -- this cell death (called necrosis) can cause acute lung injury.

They found that the medicine helped clear out 90 percent of the dead cells in the hard-hit lung. It also reduced inflammation at the site. And the most hopeful news was that half of the animals survived the injury. The work in the laboratory will continue to address questions that need answering: Will the protein be harmful to patients? How much will be enough to protect against organ failure?

Right now, there is no approved medicine to treat ischemic reperfusion. Dr. Wang said that there are 50,000 to 100,000 deaths a year related to this intestinal injury.

About The Feinstein Institute for Medical Research
Headquartered in Manhasset, NY, The Feinstein Institute for Medical Research (www.feinsteininstitute.org) is home to international scientific leaders in cancer, leukemia, lymphoma, Parkinson's disease, Alzheimer's disease, psychiatric disorders, rheumatoid arthritis, lupus, sepsis, inflammatory bowel disease, diabetes, human genetics, neuroimmunology, and medicinal chemistry. Feinstein researchers are developing new drugs and drug targets, and producing results where science meets the patient, annually enrolling some 10,000 subjects into clinical research programs.

Jamie Talan, science writer-in-residence
516-562-1232

# # #

Read the full story at http://www.prweb.com/releases/Feinstein_Institute/study/prweb3497964.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Study Reveals Protein Produced by Spleen Reduces Risk of Deadly Lung Infection
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on ... later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his ... the hospital’s 30th heart transplant recipient. , “He was playing at home, when we ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... , ... December 07, 2016 , ... AlignLife clinics nationwide ... Many children are not fortunate enough to receive bountiful gifts wrapped tightly under a ... can bring to the children of the world. , In exchange for generous donations, ...
(Date:12/7/2016)... OR (PRWEB) , ... December 07, 2016 , ... Sharon ... Water, Global Climate Change and Your Health on Voice of America, declared on her ... to call attention to the fact that when these bullies attack leaders in corporate ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers ... Season. Save Up To 33% Off Botox® and Juvederm® Products Now Through December 31, ... with Delightful Deals on Botox® and Juvederm® just in time for the ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Research and Markets has announced the addition of the ... to 2021" report to their offering. ... , , The immunohistochemistry (IHC) ... a CAGR of 7.3% during the forecast period of 2016 to 2021. ... rapidly increasing geriatric population across the globe are the primary driving the ...
(Date:12/7/2016)... 7, 2016  Palatin Technologies, Inc. ("Palatin") (NYSE ... a previously disclosed underwritten public offering of units ... as sole book-running manager, Roth Capital Partners acted ... as co-manager for the offering. "This ... net proceeds, allowing us to continue advancing bremelanotide ...
(Date:12/7/2016)... , Dec. 7, 2016 DelveInsight,s, ... report provides in depth insights on the ... the Janus Kinase 3 (JAK3) Inhibitors. The ... various stages of development including Discovery, Pre-clinical, ... and Preregistration. Report covers the product clinical ...
Breaking Medicine Technology: